PracticeUpdate: Haematology & Oncology | Vol 1.No.3 - 2016

1 / 16

The ever changing
landscape for prostate
cancer care in Australia
Following the US recommendation in 2012
against PSA testing for prostate cancer, there
has been a drop in the incidence of prostate
cancer, PSA testing and a reduction in radical
prostatectomies. Urological surgeons at the
Royal Melbourne Hospital, Dr Homi Zargar
and Dr Rajesh Nair discuss this impact locally
and how robotic surgery and new research
in prostate cancer are likely to impact clinical
practice in Australia. 4
RESEARCH NEWS AND VIEWS FROM ELSEVIER
BREAST
A negative margin of 2 mm is
the desired standard for DCIS
treated with WBRT due to a
low rate of IBTR and need for
further surgery 8
SKIN
Limited studies evaluate
the benefits of skin cancer
screening. Future research
needs to evaluate screening of
persons at high risk and effect
of screening on melanoma-
specific mortality rates 10
HAEMATOLOGY
Ipilimumab is active in patients
with relapse of haematologic
cancers after allogeneic HSCT,
but some patients experience
GVHD or immune-related
adverse events 12
Robot-assisted laparoscopic
prostatectomy vs open
radical retropubic
prostatectomy
The Lancet
Robot-assisted laparoscopic radical
prostatectomy is associated with
clinical outcomes similar to those
achieved with open radical
prostatectomy. 5
Prevalence of ESR1 mutations in cell-
free DNA and outcomes in metastatic
breast cancer: a secondary analysis
of the BOLERO-2 clinical trial
JAMA Oncology
In patients with ER-positive breast cancer
treated with aromatase inhibitors, ESR1
mutations are prevalent, with increased
disease aggressiveness associated with
Y537S and D538G mutations. 9
Improved outcomes with carfilzomib
compared with bortezomib in
relapsed multiple myeloma
regardless of prior treatment
Leukemia
Compared with bortezomib, treatment
with carfilzomib improves outcomes
in patients with relapsed multiple
myeloma regardless of prior exposure
to bortezomib or lenalidomide or the
number of prior treatment lines. 13
A comparison of survival
by site of metastatic
resection in metastatic
colorectal cancer
Clinical Colorectal Cancer
Patients undergoing MR for lung and
locoregional disease experienced a
similar survival benefit compared with
patients undergoing MR for
liver-limited disease. 14
OPINION
There is an
appreciation that
probably about
10%of menwith
advanced prostate
cancer have DNA-
repair gene defects,
and BRCA2 is the
most common.
BRCA1 and BRCA2
are themajority,
but also there are
some ATMand
other genes as well.
Dr Oliver Sartor 15
Readers Poll
What’s the ONE
medical app you
can’t live without?
Scan this code or go to
have
your say in this issue’s
PracticeUpdate
Haematology
& Oncology
Readers Poll.
IASLC 2016
Follow the 7th Latin
American Conference
on Lung Cancer as the
news rolls in on
FORMERLY HAEMATOLOGY & ONCOLOGY NEWS
VOL. 1 • No. 3 • 2016